Navigation Links
Emisphere Technologies, Inc. Announces 2008 First Quarter Financial Results
Date:5/7/2008

ing consumed as tablets are further evidence of this need.

Emisphere has two Phase III product candidates based on the compound salmon calcitonin in collaboration with Novartis Pharma AG and its development partner, Nordic Bioscience. One product is being tested for the prevention of osteoporosis and the other product for the prevention of osteoarthritis. The osteoarthritis product has the potential to be the first disease-modifying drug that could halt progression of the illness, rather than treating symptoms. Both product candidates use Emisphere's eligen(R) delivery technology to provide salmon calcitonin as a convenient oral medication. There will be over 5000 patients enrolled in Phase III trials for these products by mid-year.

Emisphere has two product candidates in Phase II, oral heparin and oral insulin, about which the Company is conducting an ongoing evaluation of strategic options. The Company will provide updates as more information emerges.
Emisphere has six product candidates in Phase I:

-- Genta Incorporated began a Phase I clinical study of oral gallium in

the third quarter of 2007;

-- A research partner has conducted Phase I studies of acyclovir; we and

our partner are reviewing the data from that program to determine

future steps;

-- Satiety and oral glucose challenge studies for both GLP-1 and PYY were

started in humans with data expected during the second quarter of this

year; and

-- Parathyroid hormone and human growth hormone are in development in

collaboration with Novartis Pharma AG

Emisphere conducts a variety of preclinical research and development programs, both in collaboration with pharmaceutical and biotechnology companies and independently. These programs are subject to ongoing review to determine whether the projects should continue and whether the independent projects are appropriate for further development or licensing.


'/>"/>
SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Emisphere Technologies, Inc. Announces Conference Call for First Quarter 2008 Financial Results
2. Emisphere Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
3. Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 2008
4. Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results
5. Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results
6. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
7. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
8. Emisphere to Host Business Strategy Conference Call on February 7
9. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
10. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
11. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... NEW YORK, March 1, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0788386/Global-Biotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechno The global outlook series ... anecdotes, market briefs, and concise summaries of ...
... 2012  Receptos Inc. today announced that the company is scheduled ... Care Conference at noon EST on Wednesday, March 7, 2012, ... Hasnain, president and chief executive officer, will provide an overview ... programs. "This is an exciting time at ...
... Laboratories, Inc. (OTCBB: UGNE), a leader in the design, ... that the Company,s senior management team will host a ... 8, 2012 at 11 a.m. ET to discuss fourth ... Interested participants and investors may access the conference call ...
Cached Biology Technology:Global Biotechnology Industry 2Global Biotechnology Industry 3Global Biotechnology Industry 4Global Biotechnology Industry 5Global Biotechnology Industry 6Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference 2Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012 2
(Date:4/23/2014)... "playwright" to their resumes in an effort to aid ... ethical issues as genomic science transitions to bedside healthcare, ... , Until now the plays of Karen H. ... and by, their peers and others in the genomics ... With Oxford University Press, publication of the book ...
(Date:4/23/2014)... is available in French and German . ... female? In humans and other mammals, the difference between sexes depends ... is present only in males, where the two sexual chromosomes are ... Y is ultimately responsible for all the morphological and physiological differences ... the case. A very long time ago, the X and Y ...
(Date:4/23/2014)... most in their mid-thirties and forties, face a ... within two decades. "Mutant" protein clusters, long blamed ... been the primary focus of therapies in development ... from Prof. Gerardo Lederkremer and Dr. Julia Leitman ... and Immunology, in collaboration with Prof. Ulrich Hartl ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Male or female? 2Male or female? 3On the defensive 2On the defensive 3
... nanometer and micron size scales could play a key ... improve the reliability, reduce the size and lower the ... by a team of scientists from the Georgia Tech ... the Naval Surface Warfare Center, the highly-uniform copper structures ...
... treat certain cancers and rheumatoid arthritis appears to greatly ... Medicine researchers report in the Journal of Clinical Investigation. ... continue to be observed long after the antibody is ... antibody, rituximab (anti-CD20), depletes B cells. Experimental evidence in ...
... or physical disabilities should not resort to a ... University. Lori Marino, senior lecturer in the Neuroscience ... Lilienfeld, professor in the Department of Psychology, to ... purveyors of what is known as dolphin-assisted therapy ...
Cached Biology News:Unique porous copper structure enables new generation of military micro-detonators 2Unique porous copper structure enables new generation of military micro-detonators 3Cancer and arthritis therapy may be promising treatment for diabetes 2Dolphin 'therapy' a dangerous fad, Emory researchers warn 2Dolphin 'therapy' a dangerous fad, Emory researchers warn 3
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
... designed for use with the ProQuest Two-Hybrid ... contains deletions in the endogenous GAL4 and ... systems. The strain also has leu2 and ... and prey vectors. MaV203 contains three GAL4 ...
Request Info...
Biology Products: